



- 1. AML 18 and AML 19**
- 2. Oxford will be one of three UK AML trial flow cytometry centers**
- 3. AML GEL and GECIP**
- 4. Anti-CD47 antibody trial**



*: Patients with AST or ALT more than 2.5 times the local upper limit of normal, or bilirubin more than twice upper limit of normal, are not eligible for the Mylotarg randomisations but will be allocated DA or FLAG-Ida



- 1. AML 18 and AML 19**
- 2. Oxford will be one of three UK AML trial flow cytometry centers**
- 3. AML GEL and GECIP**
- 4. Anti-CD47 antibody trial**

Genomics England – The main programme

